Merck tops earnings estimates on strong demand for Keytruda, new drugs even as HPV vaccine sales fall
The exterior view of the entrance to Merck headquarters in Rahway, New Jersey, on Feb. 5, 2024. Spencer Platt | Getty Images Merck on Thursday reported third-quarter revenue and adjusted earnings that topped expectations as the company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health business. But…
